Marine natural products

JW Blunt, AR Carroll, BR Copp, RA Davis… - Natural product …, 2018 - pubs.rsc.org
Covering: 2016. Previous review: Nat. Prod. Rep., 2017, 34, 235–294 This review covers the
literature published in 2016 for marine natural products (MNPs), with 757 citations (643 for …

Visceral pain

L Grundy, A Erickson, SM Brierley - Annual review of physiology, 2019 - annualreviews.org
Most of us live blissfully unaware of the orchestrated function that our internal organs
conduct. When this peace is interrupted, it is often by routine sensations of hunger and urge …

Marine pharmacology in 2016–2017: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis and antiviral …

AMS Mayer, AJ Guerrero, AD Rodríguez… - Marine drugs, 2021 - mdpi.com
The review of the 2016–2017 marine pharmacology literature was prepared in a manner
similar as the 10 prior reviews of this series. Preclinical marine pharmacology research …

Design of κ-opioid receptor agonists for the development of potential treatments of pain with reduced side effects

F Santino, L Gentilucci - Molecules, 2023 - mdpi.com
The κ-opioid receptor (KOR) has recently emerged as an alternative therapeutic target for
the development of pain medications, without deleterious side effects associated with the μ …

Endogenous opiates and behavior: 2016

RJ Bodnar - Peptides, 2018 - Elsevier
This paper is the thirty-ninth consecutive installment of the annual review of research
concerning the endogenous opioid system. It summarizes papers published during 2016 …

Modern venomics—Current insights, novel methods, and future perspectives in biological and applied animal venom research

BM von Reumont, G Anderluh, A Antunes… - …, 2022 - academic.oup.com
Venoms have evolved> 100 times in all major animal groups, and their components, known
as toxins, have been fine-tuned over millions of years into highly effective biochemical …

Peptide-derived ligands for the discovery of safer opioid analgesics

A Eliasof, LY Liu-Chen, Y Li - Drug discovery today, 2024 - Elsevier
Drugs targeting the μ-opioid receptor (MOR) remain the most efficacious analgesics for the
treatment of pain, but activation of MOR with current opioid analgesics also produces …

Nature-derived peptides: a growing niche for GPCR ligand discovery

E Muratspahić, M Freissmuth, CW Gruber - Trends in pharmacological …, 2019 - cell.com
G protein-coupled receptors (GPCRs) represent important drug targets, as they regulate
pivotal physiological processes and they have proved to be readily druggable. Natural …

Isotalatizidine, a C19-diterpenoid alkaloid, attenuates chronic neuropathic pain through stimulating ERK/CREB signaling pathway-mediated microglial dynorphin A …

S Shao, H Xia, M Hu, C Chen, J Fu, G Shi… - Journal of …, 2020 - Springer
Background Isotalatizidine is a representative C 19-diterpenoid alkaloid extracted from the
lateral roots of Aconitum carmichaelii, which has been widely used to treat various diseases …

Design of a stable cyclic peptide analgesic derived from sunflower seeds that targets the κ-opioid receptor for the treatment of chronic abdominal pain

E Muratspahić, N Tomašević… - Journal of medicinal …, 2021 - ACS Publications
The rising opioid crisis has become a worldwide societal and public health burden, resulting
from the abuse of prescription opioids. Targeting the κ-opioid receptor (KOR) in the …